In this article, Sarah Saadeh discusses how AI is shaking up the medical field and while helping in some processes is also causing commotion with concerns of harm to patients and breaching the duty of care, potential physician and insurance liability and what the regulatory landscape looks like right now advocates for Human-in-the-Loop regulation.
In this article, Lana El-Etr examines how the Amgen v. Sanofi ruling strengthens the enablement requirement, limiting overly broad genus claims while promoting innovation and ensuring accessibility to scientific advancements. She explores the broader implications of the decision, arguing that it strikes a necessary balance between protecting genuine innovation and preventing monopolies on vaguely defined scientific concepts.
In this article, Ivette Rodriguez Nieves explores the Federal Circuit’s decision in Janssen Pharmaceuticals v. Teva Pharmaceuticals and what it means for future patent approvals based on modifications.
In this article, Lana El-Etr analyzes the ethical implications of patenting genetic sequences and discusses the impact on research, patient access to treatments, and the broader implications for public health.
In this article, Ivette Rodríguez Nieves assesses how pharmaceutical companies utilize the FDA’s Orange Book patent listings, resulting in delayed entry from generic competitors. She also examines the FTC’s intervention and analyzes current concerns surrounding the pharmaceutical practices.
In this article, Cassidy Serger discusses how Contour IP Holdings, Inc. v. GoPro interprets the doctrine of patentable subject matter under 35 U.S.C. § 101 of the Patent Act.
The University of Cincinnati Intellectual Property and Computer Law Journal 